Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia in various combinations. The brainstem nuclei are prominently and severely affected in MSA, contributing to the disorder's diverse clinical manifestations. Understanding brainstem involvement is critical for accurate diagnosis, prognostication, and developing targeted therapies.
Unlike Parkinson's Disease where specific nuclei are preferentially affected, MSA demonstrates widespread brainstem pathology affecting multiple nuclei simultaneously. This widespread involvement reflects the fundamental nature of MSA as an oligodendrogliopathy with secondary neuronal degeneration. The brainstem nuclei involvement explains the early autonomic failure, the poor levodopa responsiveness, and the prominent cerebellar features that distinguish MSA from other parkinsonian syndromes. [1][2]
The brainstem serves as the critical interface between the spinal cord and higher brain regions, housing essential nuclei that control autonomic function, movement, and basic life-sustaining processes. In MSA, virtually all brainstem nuclei are affected to varying degrees.
| Nucleus | Function | Primary Neurotransmitter | MSA Involvement |
|---|---|---|---|
| Substantia nigra pars compacta (SNc) | Motor control | Dopamine | Severe (60-70% loss) |
| Pedunculopontine nucleus (PPN) | Gait, arousal | Acetylcholine | Moderate-severe |
| Red nucleus | Motor coordination | Dopamine/GABA | Moderate |
| Oculomotor nuclei (CN III) | Eye movement | Acetylcholine | Variable |
| Ventral tegmental area | Reward, motivation | Dopamine | Moderate |
| Nucleus | Function | Primary Neurotransmitter | MSA Involvement |
|---|---|---|---|
| Locus coeruleus (LC) | Arousal, autonomic | Norepinephrine | Severe (80-90% loss) |
| Dorsal raphe nucleus | Mood, sleep | Serotonin | Moderate |
| Laterodorsal tegmental nucleus (LDT) | REM sleep | Acetylcholine | Moderate |
| Pontine nuclei | Motor learning | Glutamate | Variable |
| Barrington's nucleus | Micturition | Acetylcholine | Moderate |
| Nucleus | Function | Primary Neurotransmitter | MSA Involvement |
|---|---|---|---|
| Dorsal motor nucleus of vagus (DMV) | Parasympathetic | Acetylcholine | Severe (70-80% loss) |
| Nucleus of solitary tract (NTS) | Visceral sensory | Glutamate | Moderate-severe |
| Inferior olivary nucleus (ION) | Motor coordination | Glutamate | Severe |
| Respiratory nuclei | Breathing control | Multiple | Variable |
| Raphe magnus | Pain modulation | Serotonin | Variable |
The progression of brainstem pathology in MSA follows a characteristic pattern described by Braak and colleagues:
Stage 1 (Preclinical)
Stage 2 (Early clinical)
Stage 3 (Established disease)
Stage 4 (Advanced)
Stage 5-6 (End-stage)
This staging has important implications for early diagnosis and therapeutic intervention. [3][4]
The hallmark of MSA is the presence of glial cytoplasmic inclusions (GCIs) in oligodendrocytes. Unlike Lewy bodies in Parkinson's Disease which are primarily neuronal, GCIs in MSA form in myelin-producing oligodendrocytes and drive secondary neuronal degeneration.
| Property | Description |
|---|---|
| Size | 5-15 μm diameter |
| Shape | Flame-shaped, crescent, or annular |
| Composition | α-Synuclein (phosphorylated), tau, tubulin, HSPs |
| Distribution | Throughout white matter, concentrated in affected regions |
| Density | 100-500 per mm² in severely affected areas |
The brainstem nuclei contain diverse neurotransmitter systems, all of which are affected in MSA:
Dopaminergic System
Noradrenergic System
Serotonergic System
Cholinergic System
The SNc is central to the parkinsonian features of MSA, but its pathology differs importantly from Parkinson's Disease:
Pathological Features
Clinical Correlates
The poor levodopa response in MSA reflects not just SNc degeneration but also degeneration of striatal neurons and loss of dopaminergic terminals. The pathology is more widespread than in PD, affecting both the nigrostriatal and mesocortical pathways. [5]
The locus coeruleus is one of the most severely affected nuclei in MSA:
Pathological Features
Clinical Correlates
The LC dysfunction in MSA is more severe than in PD, explaining the more prominent autonomic failure in MSA. [6][7]
The PPN is important for gait and arousal:
Pathological Features
Clinical Correlates
PPN pathology contributes significantly to the falls and gait freezing that are common in MSA and distinguish it from PD. [8]
The ION is central to the cerebellar features of MSA:
Pathological Features
Clinical Correlates
The ION in MSA shows unique hypertrophic changes that are not seen in other neurodegenerative diseases, possibly representing a compensatory response to degeneration. [9]
The DMV is critical for parasympathetic function:
Pathological Features
Clinical Correlates
The DMV is covered in detail in the dedicated page: Dorsal Motor Nucleus of Vagus in MSA
The NTS processes visceral sensory information:
Pathological Features
Clinical Correlates
The brainstem nuclei are central to autonomic control, and their degeneration produces the cardinal autonomic features of MSA:
Orthostatic Hypotension
Urinary Dysfunction
Gastrointestinal Dysfunction
| Finding | Significance |
|---|---|
| "Hot cross bun" sign | Pontine crossing fiber degeneration |
| Brainstem atrophy | Diffuse involvement |
| T2 hypointensity in SN | Iron deposition |
| Cerebellar atrophy | ION and Purkinje cell loss |
| Symptom | Treatment | Mechanism |
|---|---|---|
| Parkinsonism | Levodopa/carbidopa | Dopamine replacement (limited efficacy) |
| Orthostatic hypotension | Fludrocortisone, midodrine | Volume expansion, vasoconstriction |
| Urinary retention | Catheterization | Mechanical drainage |
| Gastroparesis | Metoclopramide, erythromycin | Prokinetic agents |
α-Synuclein targeting
Neurotrophic factors
Cell therapy
Vagus nerve stimulation
Wenning GK, et al. Multiple system atrophy. Nat Rev Dis Primers. 2022. ↩︎
Braak H, et al. Staging of brain pathology in MSA. Neurobiol Aging. 2003. ↩︎
Kalia LV, et al. Brainstem in neurodegenerative disease. Nat Rev Neurol. 2013. ↩︎
Hirayama K, et al. Substantia nigra in MSA. J Neuropathol Exp Neurol. 2011. ↩︎
Eliae A, et al. Locus coeruleus pathology in MSA. Brain. 2008. ↩︎
Kaufmann H, et al. Autonomic dysfunction in MSA. Neurology. 2004. ↩︎
Orgogozo JM, et al. Pedunculopontine nucleus in MSA. Neurology. 2019. ↩︎
Sechi G, et al. Inferior olive involvement in MSA. Mov Disord. 2007. ↩︎